Summary by Moomoo AI
On June 20, 2024, bluebird bio, Inc., a biotechnology company listed on the Nasdaq Stock Market under the trading symbol BLUE, announced the appointment of Michael Cloonan to its board of directors. Cloonan was appointed as a Class I director and his term became effective on the same day. As part of his compensation, Cloonan will receive an annual retainer of $45,000, along with an initial award of a stock option to purchase 74,775 shares and 37,350 restricted stock units of the company's common stock. These equity awards will vest over a period of three years in annual installments. Additionally, Cloonan will be entering into the company's standard indemnification agreement for directors and officers. The company confirmed that Cloonan has no familial ties with any current director or executive officer and is not involved in any transaction with the company that would necessitate disclosure under SEC regulations. The appointment is part of the company's ongoing governance and leadership structure.
